VEA
CASC

Virtus ETF Advisers’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Virtus ETF Advisers’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-19,445
Closed -$148K – 159
2016
Q1 		$148K Sell
19,445
-1,209
-6% -$9.31K 0.2% 123
2015
Q4 		$275K Buy
+20,654
New +$356K 0.75% 51

Other funds holding CASC

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
EAM
EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Virtus ETF Advisers's CASC Position: Q2 2016 in Review

Virtus ETF Advisers sold out of Cascadian Therapeutics, Inc. (CASC) in Q2 2016, closing a stake of 19,445 shares — an estimated $148K sold.

Virtus ETF Advisers first reported a position in CASC in Q4 2015 and held it in 2 quarters. The position peaked at $275K in Q4 2015. 75 funds tracked by Wall St. Rank hold CASC as of Q2 2016.

  • Virtus ETF Advisers reported no remaining Cascadian Therapeutics, Inc. position as of Q2 2016 after selling out during the quarter.
  • Virtus ETF Advisers sold 19,445 Cascadian Therapeutics, Inc. shares in Q2 2016, an estimated $148K.
  • Virtus ETF Advisers first reported a position in Cascadian Therapeutics, Inc. in Q4 2015 and held it in 2 quarters.
  • Virtus ETF Advisers's Cascadian Therapeutics, Inc. position peaked at $275K in Q4 2015.
  • 75 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q2 2016.

Based on Virtus ETF Advisers's 13F filing for Q2 2016, filed 15 Aug 2016.